Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATORM-C in Crohn's Disease
NCT07822087Phase 1Recruiting
- Sponsor
- Organoid Sciences
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in Crohn's disease (3 arms), sponsored by Organoid Sciences. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Maximum Tolerated Dose and Recommended Phase 2 Dose at 24 weeks. Started Sep 2026; status: recruiting.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07822087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822087.